Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Isofol Medical AB ( (SE:ISOFOL) ) has shared an announcement.
Isofol Medical AB has announced a significant milestone in its clinical study of arfolitixorin, a drug candidate designed to enhance cancer treatment efficacy. The company has successfully completed the second dose level in its phase Ib/II study, demonstrating that higher doses are safe and well-tolerated, which is crucial for the drug’s development given its potential to fill a treatment gap in cancer care. The study will now proceed to the third dose level, with the potential to significantly impact treatment options for colorectal cancer, a major global health concern.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate aimed at enhancing the efficacy of standard cancer treatments, particularly for colorectal cancer, which is the third most common cancer worldwide. Isofol is listed on Nasdaq Stockholm.
Average Trading Volume: 1,120,981
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK222.4M
Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.